Regulatory News:
Cellnovo Group (Paris:CLNV) ("Cellnovo" or the "Company" CLNV: EN Paris), a medical technology company marketing the first connected diabetes management platform composed of an insulin micro-pump communicating via Bluetooth with a locked-down AndroidTM smartphone, today publishes its financial calendar for the year 2019.
Events | Date * | |
Combined shareholders' meeting | February 28, 2019 | |
2018 FY results and 2019 Q1 sales | April 17, 2019 | |
Annual shareholders' meeting | June 4, 2019 | |
2019 H1 sales and results | July 24, 2019 | |
2019 Q3 sales | October 15, 2019 |
Subject to modification. Press releases are published after market closes.
About Cellnovo (Euronext: CLNV)
Cellnovo Group is global innovative medical technology company supporting the needs and desires of people with type 1 diabetes. Cellnovo has developed and markets a novel diabetes management system, which is a connected platform that aims to make life easier for people with type 1 diabetes. Cellnovo's insulin delivery system comprises a discreet, wearable micro-pump that communicates via Bluetooth Low Energy with a locked-down AndroidTM smartphone. This unique system allows optimal management of insulin dosing and delivery while ensuring freedom of movement and peace of mind. Thanks to the transmission of data in real time, the patient's status can be seamlessly monitored by family members and healthcare professionals. Cellnovo is currently participating in several major Artificial Pancreas projects with TypeZero, PEPPER and Diabeloop, to develop fully automated, closed-loop insulin delivery systems.
For more information go to www.cellnovo.com
Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 Ticker: CLNV
View source version on businesswire.com: https://www.businesswire.com/news/home/20190205005644/en/
Contacts:
Cellnovo
Chief Executive Officer
Sophie Baratte
investors@cellnovo.com
NewCap
Investor Relations
Tristan Roquet Montégon 33 1 44 71 00 16
cellnovo@newcap.eu
NewCap
Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu